<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684108</url>
  </required_header>
  <id_info>
    <org_study_id>SG301-001</org_study_id>
    <nct_id>NCT04684108</nct_id>
  </id_info>
  <brief_title>SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies</brief_title>
  <official_title>A First-in-human Phase 1 Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of SG301 in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hangzhou Sumgen Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hangzhou Sumgen Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability,&#xD;
      pharmacokinetics and preliminary efficacy in patients with relapsed or refractory multiple&#xD;
      myeloma and other hematological malignancies&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Duration of dose limiting toxicity (DLT) observation is 28 days&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with AEs and SAEs</measure>
    <time_frame>At the end of treatment phase (24 weeks)</time_frame>
    <description>To evaluate the safety and tolerability of SG301 [Adverse events (AEs), Serious Adverse Events (SAE) ]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Maximum tolerated dose (MTD) and Recommended Phase 2 dose (RP2D) for SG301</measure>
    <time_frame>At the end of treatment phase (24 weeks)</time_frame>
    <description>It will be determined based on safety, tolerability, pharmacokinetics, preliminary efficacy, and other available data by pooling and evaluating all available target attainment/engagement data, clinical PK, PD, tolerability and safety data to select the appropriate dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): AUC</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>The area under the curve (AUC) of serum concentration of the drug after the administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Cmax</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Maximum concentration(Cmax) of the drug after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary anti-tumor activity of SG301 (Objective Response Rate)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Objective response to according to IMWG response criteria for MM, Lugano criteria for lymphoma, and other standard criteria for other hematologic malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: percentage of ADA positive patients</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Number of Anti-Drug Antibodies (ADA) positive patients will be counted and percentage of ADA positive patients will be calculated to evaluate immunogenicity of SG301</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Relapsed or Refractory Multiple Myeloma</condition>
  <condition>Hematological Malignancy</condition>
  <arm_group>
    <arm_group_label>SG301</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study treatment: SG301 administered every week via intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SG301</intervention_name>
    <description>During study treatment, subjects will receive SG301 treatment via IV infusion once every week at doses of 0.01, 0.03, 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, 12.0 and 16.0mg/kg</description>
    <arm_group_label>SG301</arm_group_label>
    <other_name>An IgG1κ human monoclonal antibody (mAb) that binds to CD38</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must meet all the following criteria to be eligible for participation in this&#xD;
             study:&#xD;
&#xD;
               1. Able to understand, voluntarily participate in and willing to sign the ICF.&#xD;
&#xD;
               2. Male or female subject ≥ 18 years.&#xD;
&#xD;
               3. Histologically or cytologically confirmed hematologic malignancy that has&#xD;
                  relapsed or is refractory to standard therapy and has exhausted all available&#xD;
                  therapies or rejects other therapy. For Part 1, the expression of CD38 in&#xD;
                  subjects will be tested, but not necessarily required to be positive in order to&#xD;
                  enroll; patients with CLL and indolent NHL should have disease that requires&#xD;
                  treatment. For Part 2, NHL and HL must be CD38+ confirmed with a validated&#xD;
                  method.&#xD;
&#xD;
               4. Subjects are able to follow the study protocol and complete the trial.&#xD;
&#xD;
               5. Presence of measurable or evaluable disease.&#xD;
&#xD;
               6. Must have adequate organ function, prior to start of SG301, including the&#xD;
                  following:&#xD;
&#xD;
                    1. Bone marrow reserve: absolute neutrophil count (ANC) ≥ 1.0 ×109/L without&#xD;
                       growth factor support within 7 days prior to entry (no ANC requirement for&#xD;
                       patients with acute leukemia; ANC ≤20×109/L for leukemias, except for CLL&#xD;
                       where an elevated WBC count will not exclude patients from study entry);&#xD;
                       platelet count ≥ 75 × 109/L without transfusion within 7 days prior to&#xD;
                       entry; hemoglobin ≥ 8 g/dL or ≥ 5.6 mmol/L without transfusion within 7 days&#xD;
                       prior to entry;&#xD;
&#xD;
                    2. Hepatic: total bilirubin ≤ 1.5 times the upper limit of normal (ULN),&#xD;
                       aspartate transaminase (AST) and/or alanine aminotransferase (ALT) ≤ 2.5 ×&#xD;
                       ULN.&#xD;
&#xD;
                    3. Renal: serum creatinine ≤1.5 times the ULN or estimated creatinine clearance&#xD;
                       ≥50 mL/min (Cockroft and Gault formula&#xD;
                       [http://www.mdcalc.com/creatinine-clearance-cockcroft-gault-equation/]).&#xD;
&#xD;
                    4. Coagulation tests INR≤ 2 or prothrombin time ≤ 2×ULN.&#xD;
&#xD;
               7. Left ventricular ejection fraction (LVEF) ≥50% measured by ECHO or MUGA (only if&#xD;
                  ECHO not available) or lower limit for institutional normal value.&#xD;
&#xD;
               8. Recovery, to Grade 0-1, from adverse events related to prior anticancer therapy&#xD;
                  except alopecia, &lt; Grade 2 sensory neuropathy, lymphopenia, and endocrinopathies&#xD;
                  controlled with hormone replacement therapy&#xD;
&#xD;
               9. Subjects (women of child-bearing potential and males with fertile female partner)&#xD;
                  must be willing to use currently accepted reliable contraception method&#xD;
                  throughout the treatment period and for at least three months following the last&#xD;
                  dose of study drug. These measures include, but are not limited to, oral or&#xD;
                  implantable injections of hormonal contraceptives; intrauterine birth control&#xD;
                  ring or placement of IUS intrauterine device); or use of barrier methods such as&#xD;
                  condoms or septum and spermicide products. Postmenopausal women must have been&#xD;
                  amenorrheic for at least 12 months to be considered of non-childbearing&#xD;
                  potential. Women of childbearing age must have a negative pregnancy test.&#xD;
&#xD;
              10. ECOG score&lt;2 for dose escalation part, and ECOG ≤ 2 for dose expansion part; life&#xD;
                  expectancy ≥3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects must not have any of following:&#xD;
&#xD;
               1. Participated in any experimental treatment of any diseases within 4 weeks prior&#xD;
                  to entry.&#xD;
&#xD;
               2. Prior therapy with other monoclonal antibodies targeting the CD38 antigen or&#xD;
                  prior therapy with other IgG monoclonal antibodies within 3 months prior to first&#xD;
                  study treatment, or IgM monoclonal antibodies within 1 month prior to first study&#xD;
                  treatment&quot;.&#xD;
&#xD;
               3. Received any other anti-tumor drug therapies within 5 half-lives, or 4 weeks,&#xD;
                  whichever is shorter.&#xD;
&#xD;
               4. Known history of a Grade 3-4 allergic reaction to treatment with any humanized&#xD;
                  products.&#xD;
&#xD;
               5. Patients with symptomatic or untreated CNS metastases, or those requiring ongoing&#xD;
                  treatment for CNS metastases, including steroids and antiepileptic agents.&#xD;
&#xD;
               6. Pregnant or nursing females.&#xD;
&#xD;
               7. History of life-threatening hypersensitivity, or known to be allergic to protein&#xD;
                  drugs or recombinant proteins or excipients in SG301 drug formulation.&#xD;
&#xD;
               8. Peripheral neuropathy ≥ Grade 3.&#xD;
&#xD;
               9. Active hepatitis B or C. HBV carriers without active disease (HBV DNA titer&lt; 1000&#xD;
                  cps/mL or 200 IU/mL), or cured Hepatitis C (negative HCV RNA test) may be&#xD;
                  enrolled.&#xD;
&#xD;
              10. Subjects with known positive HIV status.&#xD;
&#xD;
              11. Active infection requiring intravenous therapy within 2 weeks prior to entry.&#xD;
&#xD;
              12. Known severe chronic obstruction respiratory disease or asthma defined FEV1% &lt;&#xD;
                  60% predicted.&#xD;
&#xD;
              13. Severe or uncontrolled cardiac disease requiring treatment, congestive heart&#xD;
                  failure NYHA III or IV, unstable angina pectoris even if medically controlled,&#xD;
                  history of myocardial infarction during the last 6 months, serious arrhythmias&#xD;
                  requiring medication (with exception of atrial fibrillation or paroxysmal&#xD;
                  supraventricular tachycardia).&#xD;
&#xD;
              14. Uncontrolled hypertension (systolic blood pressure &gt;150 mmHg and diastolic blood&#xD;
                  pressure &gt;100 mmHg), a history of hypertension crisis, or a history of&#xD;
                  hypertensive encephalopathy.&#xD;
&#xD;
              15. Received allogeneic stem cell transplantation within 3 months prior to entry, or&#xD;
                  GVHD after allogeneic stem cell transplantation requiring systemic&#xD;
                  immunosuppressants, such as cyclosporin or tacrolimus.&#xD;
&#xD;
              16. Concurrent malignancy within 2 years prior to entry other than adequately treated&#xD;
                  cervical carcinoma-in-situ, localized squamous cell cancer of the skin, basal&#xD;
                  cell carcinoma, prostate cancer under active surveillance.&#xD;
&#xD;
              17. Major surgery within 4 weeks prior to study entry; Minor surgery within 2 weeks&#xD;
                  prior to study entry.&#xD;
&#xD;
              18. Intolerant to IV infusion.&#xD;
&#xD;
              19. Any condition that the Investigator or primary physician believes may not be&#xD;
                  appropriate for participating the study.&#xD;
&#xD;
              20. Excluding subject who was treated with corticosteroid exceeding 15mg/day of&#xD;
                  prednisone or equivalent in the last 2 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lingling Liu</last_name>
    <role>Study Director</role>
    <affiliation>Hangzhou Sumgen Biotech Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lingling Liu</last_name>
    <phone>86-13466612412</phone>
    <email>liulingling@sumgenbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Sunshine Coast</name>
      <address>
        <city>Maroochydore</city>
        <state>Queensland</state>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Flynn Private Hospital</name>
      <address>
        <city>Tugun</city>
        <state>Queensland</state>
        <zip>4224</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula and Southeast Oncology</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 10, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

